Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in relapsing multiple sclerosis in China
NCT05199571Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Jul 2022; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05199571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199571.